Background
==========

Treatment of infected bone defects is challenging for orthopedic surgeons. Aggressive surgical debridement, appropriate antibiotic treatment, and reconstructive surgery play important roles in treatment of infected bone defects \[[@b1-medscimonit-26-e919925]\]. Radical debridement can reduce the failure rate and recurrence rate, but also inevitably creates segmental bone defects that are difficult to repair. Although distraction osteogenesis with external fixation, vascularized bone grafts, conventional bone grafting, and permanent acrylic spacers have been widely used, these techniques to reconstruct segmental bone defects are commonly associated with lengthy healing periods, complicated procedures, poor tolerance, and unpredictable complications. The induced membrane technique has excellent outcomes in treating significant bone defects and consists of 2 stages: 1) use of a polymethyl methacrylate (PMMA) spacer to fill the dead space to induce formation of a bioactive membrane, and 2) removal of the spacer and bone grafting \[[@b2-medscimonit-26-e919925]\]. Recently, Wu et al. \[[@b3-medscimonit-26-e919925]\] treated chronic osteomyelitis with two-stage management of the induced membrane technique, and promising results were reported. This two-stage management can also serve as an alternative for the treatment of infected bone defects \[[@b4-medscimonit-26-e919925]\].

However, the infected and nonviable tissues are sometimes difficult to differentiate from healthy tissue in a single debridement, and if the polymethylmethacrylate (PMMA) spacer is inserted at the same time, it can lead to recurrence of infection and failure of the induced membrane technique, as failure to eradicate infection has been reported at rates of 3--20.7% \[[@b3-medscimonit-26-e919925],[@b5-medscimonit-26-e919925]\]. Moreover, it is unnecessary to aggressively eliminate vascularized sclerotic tissue because the poorly vascularized parts can increase stability and decrease bone graft volume. Finally, collecting various tissue samples for bacterial culture and histopathological inspection, especially for some special pathogens (e.g., *Mycobacterium tuberculosis*), can aid diagnosis and treatment. Therefore, we use the three-stage induced membrane technique (TSIMT), including radical debridement and continuous irrigation with VSD, the insertion of a sensitive antibiotic-impregnated PMMA spacer, and the repair of bone defects.

We hypothesized that a functional outcome and thorough eradication of infection could be achieved by treating infected bone defects of the lower extremities with TSIMT. We aimed to assess the efficacy of TSIMT and identify factors that influence the outcomes of treatment.

Material and Methods
====================

Patients and inclusion criteria
-------------------------------

The Ethics Committee of our institution approved this study. The inclusion criteria were: (1) adult patients who were diagnosed with infected bone defects of the lower extremities, (2) use of TSIMT as the treatment, and (3) minimum follow-up time of at least 1 year. The exclusion criteria were: (1) patients with diseases that can influence the healing of bone and functional reconstruction of the infected lower extremity, and (2) incomplete follow-up data. All data were retrospectively collected from the information system of our hospital, including medical history (such as smoking status), radiological data, and laboratory assessments.

From January 2013 to June 2018, 41 patients were included (31 men and 10 women, average age 47.3 years, age range 29--66 years). Twenty-five patients had infected bone defects of the lower extremities caused by surgery of open reduction of internal fixation, 13 patients had defects caused by open injury, and the remaining patients had defects caused by hematogenous infection. Twenty-four male patients were active smokers. The average duration of infected bone defects was 14.0 months (range 1--36 months). Before the first stage, a mean of 2.1 procedures (range 0--5) had been performed for each patient, and all patients had received antibiotic treatment. There were 8, 24, and 9 cases of infections of the femur, tibia, and ankle, respectively. The infection sites of the femur and tibia were located on the diaphyses. Infected bone defects involving the distal tibia, astragalus, or/and calcaneus were defined as ankle infected bone defects ([Table 1](#t1-medscimonit-26-e919925){ref-type="table"}).

Surgical technique
------------------

### First-stage treatment protocol

Following comprehensive clinical, biochemical, and radiological evaluation, all patients underwent TSIMT. Empiric broad-spectrum antibiotic treatment were started when culture samples were sent for analysis. When the culture results were received, the antibiotics were changed to ones to which identified pathogens were sensitive.

The first-stage treatment consisted of multiple consecutive operative steps: radical debridement of infected tissues, lavage drainage with VSD, removal of the internal fixation material, and refixation with an external fixator, which depended on the stability of the bone.

The scope of radical debridement depended on preoperative and intraoperative investigations, such as imaging appearance, laboratory assessment (e.g., ESR and CRP), and clinical signs of infection (e.g., persistent pain and necrotic tissue of the infected site). In general, the margins of the debridement had to be beyond 5 mm of healthy bone and 2 mm of healthy soft tissue \[[@b6-medscimonit-26-e919925]\]. Different tissue samples were taken for bacterial culture and histopathological inspection at every debridement. External fixation was appropriately performed after debridement ([Figures 1](#f1-medscimonit-26-e919925){ref-type="fig"}, [2](#f2-medscimonit-26-e919925){ref-type="fig"}), except for patients who could have a stable structure without fixation ([Figure 3](#f3-medscimonit-26-e919925){ref-type="fig"}). All patients underwent lavage drainage with VSD treatment for 1 week after debridement (more than 3000 ml per day).

The number of radical debridements also depended on the degree of resolution of infection, including preoperative laboratory assessment (e.g., ESR and CRP) and culture results of lavage drainage and intraoperative investigations of surgery (e.g., persistence of necrotic tissue of the infected site). If the infection had been well-control, the patient received the treatment of the second stage; if not, the patient underwent repeat debridement surgery.

### Second-stage treatment protocol

The second stage was the filling of dead space with antibiotic-impregnated PMMA spacers and reconstruction of soft-tissue defects. The choice of antibiotics was made according to the results of bacterial culture and histopathological inspection in stage one. Patients with general bacterial infection received 40 g PMMA with addition of 0.5 g gentamicin mixed with 2--3 g Vancomycin powder, and those with tuberculous infection also received 1 g streptomycin powder. Patients received intravenous antibiotic therapy throughout the first 2 stages. Most patients were discharged after 2 weeks of the second-stage treatment and usually received at least 4 weeks of oral antibiotic therapy, except for patients with tuberculosis infection, who underwent least 1 year of antituberculosis therapy. Muscular or fasciocutaneous flaps (e.g., anterolateral thigh flap) were used for patients with soft-tissue defects ([Figure 4](#f4-medscimonit-26-e919925){ref-type="fig"}). Subsequently, patients performed partial weight-bearing rehabilitation to avoid osteoporosis.

### Third-stage treatment protocol

When normal values of ESR and CRP, and healing of the sinus tract and flap were observed, the third stage was performed, which consisted of removal of the spacer, morselized bone grafting with an autograft from the ilium/fibula or a mixed allograft, and change of final fixation.

When the status of surrounding soft tissue was good and the discomfort level was acceptable, patients received an internal fixator (e.g., LCP plate) as the final fixation. If the articular surface had been destroyed, articular fusion using internal fixation was performed (e.g., ankle infected bone defect). Cancellous bone autograft from an iliac crest and fibula ([Figure 3](#f3-medscimonit-26-e919925){ref-type="fig"}) was usually the best choice. If insufficient material was available, combining a cancellous bone autograft with allograft (less than 40%) was also an alternative.

Postoperative follow-up
-----------------------

Postoperative radiologic images and clinical results of treatment, including the rate of cure, time to union, the Lower Extremity Functional Scale (LEFS) \[[@b7-medscimonit-26-e919925]\] were recorded. Bone union was defined by 2 continuous cortices on 2 different views. Infection cure was defined by eradication of the clinical infectious signs and normalization of ESR and CRP. The LEFS consisted of 20 functional leg activities, of which the highest score was 80.

Statistical analysis
--------------------

Quantitative and qualitative variables were reported separately as mean and standard deviation and number. Data were analyzed using the SPSS 21.0 statistical software (SPSS, Inc., Chicago, IL, USA). An independent-samples *t* test was used for comparison of continuous variables. The significance threshold was set at 0.05 in a two-sided test ([Table 2](#t2-medscimonit-26-e919925){ref-type="table"}).

Results
=======

In the first stage, 17 patients underwent debridement 2--4 times. One patient with a femur infected bone defect underwent 4 debridements, and 2 debridements were performed for 3 patients with femur defects, 10 patients with tibia infected bone defect, and 3 patients with ankle infected bone defect. Only 3 patients with ankle infected bone defects; they did not receive fixation because the bone defects could be treated as lacunar bone defects and the bone construction can remain stable after debridement, which reached the demand for treatment, so they did not need to get external fixation. The remaining patients all received an external fixator for stabilizations. After the first stage, 34 patients had positive cultures; one of them and 2 patients with negative culture results were diagnosed with *Mycobacterium tuberculosis* infection in the ankle according to the biopsy results ([Table 3](#t3-medscimonit-26-e919925){ref-type="table"}).

The second stage was performed after a mean of 1.5 weeks (range 1--4 weeks). In the second stage, all results of bacterial culture were negative. The final bone defects after debridement had a mean size of 6.0 cm (range 3.0--10.0 cm). According to the results of the bacterial culture and histopathological inspection of the first stage, vancomycin powder was mixed with PMMA for 38 patients, and 3 patients received vancomycin and streptomycin powder. Only 1 patient with an ankle infected bone defect had an anterolateral thigh flap placed to cover the soft-tissue defect. The mean spacer placing time was 13.6 weeks (range 10--24 weeks).

At the third stage, 4 patients with femur infected bone defect and 6 patients with tibial infected bone defect received ilium and allograft as bone grafts, 9 patients with ankle infected bone defect received fibula as bone grafts, and the remaining patients all received bone autografts from iliac crests. For final fixation, 5 patients with femur infected bone defect and 4 patients with tibial infected bone defect received internal fixation (LCP plate) as the final fixation. Articular fusion using internal fixation was performed in the 9 patients with ankle infected bone defect, such as tibio-talo-calcaneal fusion. There were no intra- or postoperative complications.

Forty-one patients underwent a mean of 8.5 weeks (range 8--11 weeks) of antibiotic therapy in total, and 3 patients with tuberculosis underwent least 1 year of antituberculosis therapy. The mean follow-up period was 23.3 months (range 12--38 months). Bony union was achieved in 100% of cases, with a mean of 7.5 months (range 4--15 months after the third stage). No recurrence was found, and no more supplementary procedures were required. The mean LEFS scores before the first stage, at 1 year after stage 3 and at the last follow-up were 43.3 (38--52), 58.9 (49--69), and 68.4 (59--76), with an average of 85.5% (range 73.8--95%) of maximal function ([Table 1](#t1-medscimonit-26-e919925){ref-type="table"}).

By analysis of the related factors that can affect the bone union time and the change of LEFS after 1 year of the third stage, we discovered that bone defect size, type of bone graft, debridement times, and spacer-placing time did not influence bone union time or the change of LEFS after 1 year of the third stage (p\>0.05). Advanced age, longer duration of infected bone defects, active smoking, and external fixation method had an adverse impact on bone union time and the change of LEFS after 1 year of the third stage (p\<0.05) ([Table 2](#t2-medscimonit-26-e919925){ref-type="table"}).

Discussion
==========

Principle of treatment and reasons why we use TSIMT for infected bone defects of the lower extremities
------------------------------------------------------------------------------------------------------

With rising numbers of surgeries and use of implants worldwide, the number of infections is rising \[[@b8-medscimonit-26-e919925]\]. Infected bone defects are characterized by a progressive inflammatory process caused by pathogens, leading to bone destruction and sequestrum formation. Difficulties in treatment concern 2 aspects: 1) control of the infection, and 2) addressing osseous defects \[[@b9-medscimonit-26-e919925]\]. Aggressive surgical debridement, appropriate antibiotic treatment, and reconstructive surgery play important roles in dealing with infected bone defects and in ensuring long-term success \[[@b1-medscimonit-26-e919925]\]. Concerning debridement, more surgeons are aware of the importance of radical debridement to remove all devitalized and infected tissues, including skin, sinus tract, soft tissue envelope, and bone, until vital bleeding tissue remains ('paprika sign') \[[@b10-medscimonit-26-e919925]\]. Radical debridement should not be limited by the fear of enlarging the tissue defects, as inadequate debridement has a high rate of recurrence \[[@b11-medscimonit-26-e919925],[@b12-medscimonit-26-e919925]\].

Although the induced membrane technique has been widely used for infected bone defects, the reasons why we used TSIMT were as follows: 1) As infected, nonviable tissue may be hard to differentiate from normal tissue by one debridement firstly, serial debridement with VSD to eradicate the nidus is necessary to prevent a recurrence \[[@b13-medscimonit-26-e919925]\]. 2) To eradicate the infection completely, using the two-stage treatment, the scope of debridement may far exceed the actual debridement range. All necrotic bone was removed down to bleeding bone ('paprika sign'), but sclerotic bone need not necessarily be sacrificed as long as it is vascularized. Even poorly vascularized parts can serve an important role in the stability and decrease the volume of bone grafts. 3) using three-stage treatment, we had the time to take different tissue samples for bacterial culture and histopathological inspection, providing the best possibility to use a sensitive antibiotic systemically and locally to decrease recurrence, especially for some special pathogens such as *Mycobacterium tuberculosis*. At the same time, we could reassess the condition several times and decide whether it was appropriate to proceed to the next stage, decreasing the rate of recurrence.

How to use antibiotics systematically and locally?
--------------------------------------------------

Antibiotic therapy exerts its full adjunctive effect after radical surgical debridement as a treatment for residual pathogens. Empiric antibiotic treatment must start as soon as the culture samples have been obtained if there is a sinus or soft-tissue defects. In the case of culture-negative infection, a second-generation cephalosporin is recommended until the results of intraoperative bacterial culture and histopathological inspection are obtained. Most authors recommend 4--6 weeks of antibiotic therapy, which is based on the time (3--4 weeks) needed for the revascularization of the bone, which causes the antibiotics to work more effectively \[[@b14-medscimonit-26-e919925]\]. All recommendations are empirical, and the duration of concomitant systemic antibiosis and the positive effects of prolonged antibiotic therapy are still unclear \[[@b14-medscimonit-26-e919925]\]. In fact, prolonged antibiotic treatment increases the risk of adverse effects and antibiotic resistance, even for planktonic bacteria \[[@b14-medscimonit-26-e919925]\]. Planktonic bacteria may be eliminated rather quickly; however, biofilm-embedded pathogens require up to 1000 times the minimum inhibitory concentration (MIC), and it is usually not possible to achieve this high of a therapeutic concentration with systemic antibiotic therapy \[[@b15-medscimonit-26-e919925]\].

To reduce systemic adverse effects and provide an effective local concentration of antibiotics for the treatment of infected bone defects \[[@b16-medscimonit-26-e919925]\], the combination of systemic and local antibiotic treatment becomes preferable and may be a valuable tool against orthopedic infections. Research has also found that antibiotic administration through the oral or parenteral route makes no difference when treating infected bone defects if the bacteria are susceptible to the antibiotic used \[[@b11-medscimonit-26-e919925]\].

A local carrier consisting of antibiotics and PMMA provides a much higher concentration of antibiotics to the surrounding tissues than does intravenous antibiotic therapy \[[@b17-medscimonit-26-e919925],[@b18-medscimonit-26-e919925]\]. With regard to the choice of antibiotics to mix with PMMA, the results of bacterial culture and histopathological inspection matter greatly. Glycopeptides and aminoglycosides are most commonly used \[[@b9-medscimonit-26-e919925]\] because they are broad-spectrum, high local concentrations are released from PMMA cement, and they are thermostable \[[@b1-medscimonit-26-e919925]\]. Gram-positive pathogens that cause bone infection are mainly susceptible to vancomycin. Most gram-negative bacteria are susceptible to tobramycin \[[@b9-medscimonit-26-e919925]\]. Vancomycin and tobramycin have the lowest cytotoxic effect \[[@b19-medscimonit-26-e919925]\] and rare systemic adverse effects after local application \[[@b20-medscimonit-26-e919925]\]. Moreover, the type and extent of infected bone defects, medical comorbidities, isolated organism(s), and whether the infection is recurrent are very important \[[@b21-medscimonit-26-e919925]\]. In polymicrobial infections, a combination of antibiotics can be used to reduce the recurrence rate \[[@b22-medscimonit-26-e919925]\]. Even for patients with strong evidence of monomicrobial infection (symptoms with the typical clinical appearance and unambiguous culture), it seems best to reserve application of a single local antibiotic in order to address the problem of potentially undetected polymicrobial infection \[[@b9-medscimonit-26-e919925]\]. Four grams of vancomycin per 40 g of PMMA cement was used for the infected bone defects \[[@b23-medscimonit-26-e919925]\]. An average of 3.4 batches of cement with a mean of 10.5 g of vancomycin and 12.5 g of gentamicin has been used for infected bone defects without systemic toxicity \[[@b16-medscimonit-26-e919925]\]. Therefore, the 2 g of vancomycin were mixed with per 40 g of PMMA with the addition of 0.5 g of gentamicin for general infection, and 2 g of vancomycin and 1 g of streptomycin with 40 g of PMMA with addition of 0.5 g of gentamicin for patients with tuberculosis were used.

Advantages and best timing of PMMA spacer
-----------------------------------------

Apart from providing extremely high concentrations of antibiotics, PMMA can fill the dead space and induce the formation of a membrane \[[@b17-medscimonit-26-e919925]\]. The induced membrane technique is simple and useful for addressing critical bone size defects, with a high rate bone union that ranges from 82.6% to 100% \[[@b2-medscimonit-26-e919925],[@b24-medscimonit-26-e919925]\]. One-stage cancellous bone grafts can undergo bone necrosis and resorption when the bone defects exceeds 2 cm \[[@b25-medscimonit-26-e919925]\]. However, the induced membrane technique can revascularize the bone graft and prevent bone resorption; moreover, the induced membrane is highly vascularized, which can provide an osteogenic microenvironment to support bone lateral regeneration by secreting several growth factors, including VEGF and BMP-2 \[[@b2-medscimonit-26-e919925]\]. Research also found that the cement spacer can prevent fibrous tissue from invading into the bone defect site, provide stability, and facilitate the repairing of the affected soft tissue, which is helpful for the eradication of infection \[[@b26-medscimonit-26-e919925]\]. Complete soft-tissue coverage is critical for the formation of the membrane, and muscular or fasciocutaneous flaps can be used if necessary. Muscle flaps are preferable for reducing the recurrence rates of chronic infected bone defects because they not only can manage dead space and provide soft-tissue coverage, but also prevent contamination, improve vascularity, and enhance the delivery of antibiotics \[[@b27-medscimonit-26-e919925]\].

There is no consensus regarding the timing of PMMA spacer removal and bone grafting \[[@b24-medscimonit-26-e919925]\]. Currently, 4 to 8 weeks is thought to be the best time for bone graft because this period has the highest level of vascularization and growth factors and the best status of the induced membrane \[[@b2-medscimonit-26-e919925]\]. Auregan et al. \[[@b26-medscimonit-26-e919925]\] found that the best timing to approach the induced membrane depended on the vascularization of the segment; when more vascular axes vascularized the segment, the membrane was vascularized and usable earlier. Therefore, the time interval is longer in femurs and ankles compared with tibias. Due to the inflammation (ESR and CRP), poor soft-tissue coverage, and type of pathogens, the timing of PMMA spacer removal in our study was later, at least 10 weeks, and approximately 6 months in patients with tubercle bacillus.

Bone grafts and stabilization
-----------------------------

For bone grafts, cancellous bone autografts from an iliac crest and fibula are the best choice. If not enough material is available, combining a cancellous bone autograft with allograft (less than 40%) is also an alternative \[[@b26-medscimonit-26-e919925]\]. Cancellous bone can also be obtained through the technique of RIA (reaming irrigation aspiration) \[[@b28-medscimonit-26-e919925]\].

The option of bone stabilization is influenced by several factors, including the characteristics of the defects (e.g., the severity of infection and the location and size), the status of the affected soft tissue, firm fixation needed for therapy, and the patient's tolerance \[[@b3-medscimonit-26-e919925]\]. Along with debridement, the infected or unhealthy tissues should be considered to be contaminated, and the surface of internal implants can act as a substratum for the attachment of bacteria and formation of biofilms \[[@b29-medscimonit-26-e919925]\]. Therefore, in the first stage, traditional external fixation was treated as the best choice for eradication of the infection and protection of the affected soft tissue. Studies have also used locking compression plates as external fixation, which are versatile and have good patient tolerance and satisfactory outcomes \[[@b30-medscimonit-26-e919925],[@b31-medscimonit-26-e919925]\]. Additionally, bone resorption and nonhealing have been reported to occur in cases with low stable fixation \[[@b32-medscimonit-26-e919925]\]. As long as the local antibiotic concentrations are higher than the dosage required for eliminating biofilm-embedded bacteria (more than 100 mg/l), the risk of contamination of alloplastic material is low \[[@b9-medscimonit-26-e919925]\]. When mixing bone grafts with antibiotics, their storage capability for antibiotics exceeds those of PMMA and other carriers, and the entire amount is available, leading to high local concentrations and a prolonged biofilm-active release \[[@b9-medscimonit-26-e919925]\]. These capacities make reconstruction and internal stabilization at the same time possible in the third stage.

What factors influence the outcomes of treatment?
-------------------------------------------------

We analyzed the related factors involved in the bone union time and improvement of function of the lower extremities, which was defined as the difference between LEFS measured before first stage and about 1 year after the third stage, and discovered that defect size, type of bone graft, debridement times, and spacer-placing time did not influence bone union time or the change in LEFS after 1 year of the third stage. The findings were previously reported \[[@b3-medscimonit-26-e919925],[@b33-medscimonit-26-e919925],[@b34-medscimonit-26-e919925]. The bone union time and improvement of lower-extremities function in a limited time were more affected by age, duration of infected bone defects, active smoking, and final fixation method in our series. As with smoking, longer duration of infected bone defects means longer immobilization, persistence of infection, and more surgeries that can destroy local blood supply and have an adverse impact on bone union and improvement of function of the lower extremities. Research \[[@b35-medscimonit-26-e919925]\] found that smoking significantly increased the risk of nonunion of fractures but non-significantly increased time to union in all fractures, and the impact of smoking on bone union time found in our research may be attributable to our small sample size. Internal fixation can provide sufficient stabilization and allow resumed weight-bearing owing to the good toleration, which can facilitate the union and recovery of function. Although research found that age did not influence lower-extremity improvement \[[@b3-medscimonit-26-e919925]\], the effect of the involved factors on the improvement of LEFS was not time-limited. With a long duration of rehabilitation, the impact of age on lower-extremity improvement may be less significant, but further research is needed.

The present study has certain limitations. First, the study population in our research was small and it was a retrospective study. Second, some variables were not assessed, such as the joint range of motion. Randomized controlled studies with larger sample sizes are needed.

Conclusions
===========

TSIMT showed excellent outcomes in the treatment of infected bone defects of the lower extremities, which can be used to radically clean the infected sites, decrease the rate of recurrence, and effectively facilitate the reconstruction of bone defects. Advanced age, longer duration of infected bone defects, active smoking, and external fixation method had an adverse effect on bone union time and the recovery of infected extremities in a limited time (1 year after TSIMT). Further research is needed to determine the best time for bone grafting, more appropriate skeletal fixation, and to assess long-term effects of the factors involved on recovery of the infected extremities.
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![A representative case. A 54-year-old woman with tibial infected bone defect underwent TSIMT. Anteroposterior (**A1, A3**) and lateral (**A2, A4**) radiograph by X-ray and CT before first-stage surgery; (**B1, B2**) photos taken before and after debridement during the operation. Anteroposterior (**C1, D1**) and lateral (**C2, D2**) radiographs after second- and third-stage surgery, respectively. Anteroposterior (**E1**) and lateral (**E2**) radiographs taken 9 months after third-stage surgery.](medscimonit-26-e919925-g001){#f1-medscimonit-26-e919925}

![A representative case. A 62-year-old man with femoral infected bone defect underwent TSIMT. Anteroposterior (**A1, A3**) and lateral (**A2, A4**) radiograph by X-ray and CT before first-stage surgery; anteroposterior (**C1, D1**) and lateral (**C2, D2**) radiographs after second- and third-stage surgery, respectively. (**B, F, G**) Photos taken after debridement, insertion of PMMA, and bone graft. Anteroposterior (**E1**) and lateral (**E2**) radiographs taken 10 months after third-stage surgery.](medscimonit-26-e919925-g002){#f2-medscimonit-26-e919925}

![A representative case. A 50-year-old man with ankle infected bone defect caused by tubercle bacillus underwent TSIMT. Anteroposterior (**A1, A3**) and lateral (**A2, A4**) radiographs by X-ray and CT before first-stage surgery; anteroposterior (**B1, C1**) and lateral (**B2, C2**) radiograph after second- and third-stage surgery, respectively. Anteroposterior (**D1**) and lateral (**D2**) radiographs taken 10 months after third-stage surgery. (**E**) Pathologic findings.](medscimonit-26-e919925-g003){#f3-medscimonit-26-e919925}

![A representative case. A 38-year-old man with ankle acute infected bone defect and a significant soft-tissue defect underwent TSIMT. Anteroposterior (**A1**) and lateral (**A2**) radiographs by X-ray before the first stage; (**A3**) was taken at the first debridement surgery; anteroposterior (**B1**) and lateral (**B2**) radiographs after the second stage; (**B3**) was taken after the second stage with the flap. Anteroposterior (**C1, C3**) and lateral (**C2, C4**) radiographs taken 10 months after third-stage surgery.](medscimonit-26-e919925-g004){#f4-medscimonit-26-e919925}

###### 

General patient data.

  ------------------------------------------------------------------------------------------------ -----------------
  Patient number (Male, Female), n                                                                 41.0 (31,10)
  Mean age (range), y                                                                              47.3 (29--66)
  Infected site (femur, tibia, ankle), n                                                           8, 24, 9
  Average duration of infected bone defects (range), m                                             14.0 (1--36)
  Mean previous surgeries before the first stage (range), n                                        2.1 (0--5)
  Mean final bone defect (cm)                                                                      6.0 (3.0--10.0)
  Debridement times, n                                                                             1.5 (1--4)
  Duration of systemic antibiotics (week)[\*](#tfn1-medscimonit-26-e919925){ref-type="table-fn"}   8.5 (8--11)
  PMMA spacer placing time (weeks)                                                                 13.6 (10--24)
  Follow-up time (months)                                                                          23.3 (12--38)
  Mean initial mean LEFS score                                                                     43.3 (38--52)
  Mean LEFS score at one year after stage three                                                    58.9 (49--69)
  Mean final mean LEFS score                                                                       68.4 (59--76)
  Union time (months)                                                                              7.5 (4--15)
  ------------------------------------------------------------------------------------------------ -----------------

3 patients with tuberculosis excluded.

###### 

Outcome between different groups[\*](#tfn2-medscimonit-26-e919925){ref-type="table-fn"}.

  Group (n)                                                                       Bone union time (months)   P value     Difference of LEFS[\*\*](#tfn3-medscimonit-26-e919925){ref-type="table-fn"}   P value
  ------------------------------------------------------------------------------- -------------------------- ----------- ----------------------------------------------------------------------------- ---------
  Age                                                                                                                                                                                                  
   \<40 y (15)                                                                    5.60±0.99                  0.000       18.6±4.10                                                                     0.001
   ≥40 y (26)                                                                     8.65±2.92                  13.8±3.75                                                                                 
  Duration of infected bone defects                                                                                                                                                                    
   \<12 months (13)                                                               5.31±1.03                  0.000       18.2±5.12                                                                     0.009
   ≥12 months (28)                                                                8.57±2.78                  14.4±3.61                                                                                 
  Smoking                                                                                                                                                                                              
   Yes (24)                                                                       8.54±3.04                  0.002       13.7±3.51                                                                     0.001
   No (17)                                                                        6.12±1.69                  18.3±4.37                                                                                 
  Debridement times                                                                                                                                                                                    
   1 time (24)                                                                    7.25±2.75                  0.445       16.1±3.82                                                                     0.427
   ≥2 times (17)                                                                  7.94±2.93                  14.9±5.30                                                                                 
  Length of bone defect                                                                                                                                                                                
   \<5 cm (8)                                                                     6.88±3.05                  0.465       15.8±6.94                                                                     0.947
   ≥5 cm (33)                                                                     7.70±2.78                  15.6±3.79                                                                                 
  Type of bone graft                                                                                                                                                                                   
   Autograft (31)                                                                 7.26±2.63                  0.269       16.3±4.01                                                                     0.071
   Mixed bone graft (10)[\#](#tfn4-medscimonit-26-e919925){ref-type="table-fn"}   8.40±3.31                  13.4±5.27                                                                                 
  Final stabilization method                                                                                                                                                                           
   Internal fixation (18)                                                         6.06±1.66                  0.001       18.0±4.26                                                                     0.002
   External fixation (23)                                                         8.70±3.01                  13.7±3.73                                                                                 
  Spacer placing time                                                                                                                                                                                  
   \<12 weeks (9)                                                                 7.33±2.12                  0.810       15.0±4.24                                                                     0.649
   ≥12 weeks (32)                                                                 7.59±3.00                  15.7±4.58                                                                                 

Analyzed using an independent-samples *t* test;

difference of LEFS=LEFS measured about one year after stage 3 -LEFS measured at the beginning of stage one;

autograft and allograft.

###### 

Bacteria isolated and pathological report in stage 1.

  Number of patients                                         Bacteria                                 Pathological report
  ---------------------------------------------------------- ---------------------------------------- --------------------------------------------------------------------------------------------------
  9                                                          *S. aureus*                              Chronic osteomyelitis (8 patients), chronic osteomyelitis+Granulomatous inflammation (1 patient)
  4                                                          MRSA                                     Chronic osteomyelitis
  4                                                          *S. epidermidis*                         Chronic osteomyelitis
  3                                                          *E. cloacae*                             Chronic osteomyelitis
  4                                                          *P. aeruginosa*                          Chronic osteomyelitis
  1                                                          *A. baumannii*                           Chronic osteomyelitis
  2                                                          *K. pneumoniae*                          Chronic osteomyelitis
  2                                                          *P. mirabilis*                           Chronic osteomyelitis
  2                                                          *S. aureus, E. cloacae*                  Chronic osteomyelitis
  1[\*](#tfn6-medscimonit-26-e919925){ref-type="table-fn"}   *S. aureus, E. faecalis*                 Chronic osteomyelitis
  1[\*](#tfn6-medscimonit-26-e919925){ref-type="table-fn"}   *C. sporogenes, P. aeruginosa*           Chronic osteomyelitis
  1                                                          *S. aureus, P. aeruginosa, E. cloacae*   Chronic osteomyelitis
  7                                                          Negative culture result                  Chronic osteomyelitis (5 patients), osteomyelitis+Granulomatous inflammation (2 patients)

MSSA -- methicillin-susceptible *Staphylococcus aureus*.

The bacteria isolated from first and second debridement is*S. aureus/C. sporogenes* and *E. cloacae/P. aeruginosa*.
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